STSA Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.

$6.60
As of 06/24/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/31/1997
Outstanding shares:  31,529,417
Average volume:  585,585
Market cap:   $179,717,677
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    80405P107
ISIN:        US80405P1075
Sedol:      BJTHPR6
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.90
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy